Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Marc Ladanyi, MD"'
Autor:
Kathryn C. Arbour, MD, Eusebio Manchado, PhD, Matthew J. Bott, MD, Linda Ahn, NP, Yosef Tobi, BA, Andy Ai Ni, Helena A. Yu, MD, Alyssa Shannon, BA, Marc Ladanyi, MD, Victoria Perron, BS, Michelle S. Ginsberg, MD, Amanda Johnson, BA, Andrei Holodny, MD, Mark G. Kris, MD, Charles M. Rudin, MD, PhD, Piro Lito, MD, PhD, Neal Rosen, MD, PhD, Scott Lowe, PhD, Gregory J. Riely, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100256- (2022)
Introduction: Somatic KRAS mutations occur in 25% of patients with NSCLC. Treatment with MEK inhibitor monotherapy has not been successful in clinical trials to date. Compensatory activation of FGFR1 was identified as a mechanism of trametinib resist
Externí odkaz:
https://doaj.org/article/08ab67b4ab914fc8921cb36a60feebfe
Autor:
David H. Abramson, MD, Diana Mandelker, MD, PhD, Jasmine H. Francis, MD, Ira J. Dunkel, MD, A. Rose Brannon, PhD, Ryma Benayed, PhD, Michael F. Berger, PhD, Maria E. Arcila, MD, Marc Ladanyi, MD, Danielle Novetsky Friedman, MD, Gowtham Jayakumaran, MS, Monica S. Diosdado, MA, Melissa A. Robbins, MPH, Dianna Haggag-Lindgren, BS, Neerav Shukla, MD, Michael Walsh, MD, Prachi Kothari, DO, Dana W.Y. Tsui, PhD
Publikováno v:
Ophthalmology Science, Vol 1, Iss 1, Pp 100015- (2021)
Purpose: Analysis of circulating tumor DNA (ctDNA) in the plasma of patients with retinoblastoma and simulating lesions. Design: Retrospective cross-sectional study of the association of plasma ctDNA from retinoblastoma and simulating lesions with di
Externí odkaz:
https://doaj.org/article/9c664857dfd245da8feebe8a194e22df
Autor:
Maria E. Arcila, MD, Soo-Ryum Yang, MD, Amir Momeni, MD, Douglas A. Mata, MD, Paulo Salazar, BS, Roger Chan, BS, Daniela Elezovic, BS, Ryma Benayed, PhD, Ahmet Zehir, PhD, Darren J. Buonocore, MD, Natasha Rekhtman, MD, Oscar Lin, MD, Marc Ladanyi, MD, Khedoudja Nafa, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 3, Pp 100077- (2020)
Introduction: For patients with advanced NSCLC, cytologic samples may be the only diagnostic specimen available for molecular profiling. Although both rapid and comprehensive assessment are essential in this setting, an integrated multitest approach
Externí odkaz:
https://doaj.org/article/bb5a2173dfd147caaec46e5ca0cb4e9f